PPT-Anticoagulation for VTE: How Long?

Geoffrey Barnes MD MSc University of Michigan GBarnesMD May 14 2020 Disclosures Grants PfizerBristolMyers Squibb Blue Cross Blue Shield of Michigan NHLBI AHRQ Consulting PfizerBristolMyers Squibb Janssen Portola AMAG Pharmaceuticals. Seven. Venous Disease Coalition. Long-Term Management of VTE. VTE . T. oolkit. Long-Term Treatment of DVT/PE:. 2 options. VTE . T. oolkit. LMWH S/C. Oral Anticoagulation (INR 2.0 - 3.0). 5-7 d. 3 . Geoffrey Barnes, MD. Cardiovascular and Vascular Medicine. University of Michigan, USA. 1. st. Qatar Conference on . Safe Anticoagulation Management. February 27, 2015. Outline. VTE Recurrence Risk. how long to treat?. Eliot Williams, MD PhD. Department of Medicine. Division of Hematology & Medical Oncology. 3 months of anticoagulant treatment is both necessary and sufficient for most patients after a first episode of VTE. How Do Real-World Data Fit In? . Program Goals. VTE Is a Leading Cause of Death Worldwide. NOACs: VTE Clinical Trials. Real-World Data. XALIA. A Prospective, Noninterventional Study. EINSTEIN-DVT and XALIA: Outcomes. . . Feb 08/2014. Hanadi. . Alhozali,MBBS,ABIM,FRCPC. Assistant professor consultant internal medicine and Nephrology KAUH/Jeddah. Glomerular- based disease and Renal disease in pregnancy. Objectives. . Alan Brush, MD, FACP. Chief, Anticoagulation Management Service. Harvard Vanguard Medical Associates. Language. . .. Suggestions . vs. . Recommendations: . based on the weight of evidence. Loading . Judicious Use of Anticoagulation: A Case-Based Approach Michael B. Streiff, MD, FACP Associate Professor of Medicine and Pathology Division of Hematology Medical Director, Johns Hopkins Anticoagulation Management Service and Outpatient Clinics Thomas W. Butler, M.D., F.A.C.P.. Associate Professor of Clinical Interdisciplinary Oncology. University of South Alabama. Mitchell Cancer Institute. June 22, 2017. Thomas W. Butler, M.D.. Nothing to disclose. An Educational Slide Set . American Society of Hematology 2018 Guidelines . for Management of Venous Thromboembolism. Slide set authors: . E. ric. Tseng MD . MScCH. , University of Toronto. Daniel Witt PharmD, University of Utah. Pregnancy for women with complex needs. Maternity service update. Antenatal VTE assessment. Dr Lauren Ward – CCG clinical lead for preconception and antenatal care. Background – venous thromboembolism. Thrombosis Fellow. VTE is chronic disease. Recurrence rate after initial VTE up to 24.6% after 5 years. Clinical need to identify individuals at increased risk of recurrent VTE. VTE terminology. Provoked . Dr Henan Dh Skheel. Department Of . Obs&Gyn. 2020. Venous . thromboembolism.  (. VTE) is a collective term that describes deep vein thrombosis (DVT) and pulmonary embolism (PE).. Venous thromboembolism is a leading cause of . introduction. Twenty percent of maternal deaths in the United States during that period were attributed to PE.. . Inherited . thrombophilias. are associated with an increased risk of venous . thromboembolism. An Educational Slide Set . American Society of Hematology 2020 Guidelines . for Management of Venous Thromboembolism. Slide set author: . Siraj . Mithoowani. MD, MHPE (McMaster University). Clinical Guidelines.